We evaluated mid-term results of the multicenter EVT/Guidant aortouniiliac endograft (AI) trial and ascertained the durability of this endovascular technique in patients unable to undergo standard bifurcated endografting. Methods: From November 1996 to December 1998, 121 patients were enrolled to receive the AI device on the basis of complex iliac artery anatomy contraindicating bifurcated endografting. Clinical data were centrally collected, and radiographic data were evaluated by core facility. 
Since the introduction of endovascular repair of abdominal aortic aneurysm, a major limitation to the vascular surgeon's ability to use these methods has been anatomic constraints of the aneurysm. One of these constraints continues to be complex iliac artery anatomy. Specifically, an ectatic or frankly aneurysmal iliac artery, as well as iliac tortuosity or occlusive disease, may lead to inadequate graft-vessel landing zones or difficulty in tracking and placing endovascular devices.
In such circumstances, some iliac limitations of endovascular repair may be overcome with an aortouniiliac (AI) device in conjunction with femorofemoral crossover bypass grafting when one iliac artery is suitable for access and device deployment. Several studies have confirmed the feasibility and short-term success of placing such a repair configuration. [1] [2] [3] [4] Further, the US Food and Drug Administration (FDA) has recently approved the EVT/Guidant AI device for use in such cases. However, several questions remain regarding late success after placement of this en-dograft configuration and have tempered enthusiasm for its use. The durability of femorofemoral bypass grafting is poorly defined in this patient population and remains suspect. The significance of altered pelvic perfusion with various forms of internal iliac artery exclusion also remains undefined. Finally, the durability of contralateral common or combined external-internal iliac artery occlusion required during repair remains unclear, inasmuch as endoleak and distal embolization are conceivable consequences. In addition to these end points unique to AI with femorofemoral bypass, aneurysm enlargement, rupture, endoleak, reduced limb flow, and associated repeated interventions, as well as late death, are clearly important in patients with aneurysm treated with endografting. Therefore, in an attempt to better address these concerns, this report presents the continuing mid-term follow-up of the EVT/Guidant AI device trial.
PATIENTS AND METHODS
Description of the EVT/Guidant AI device, implantation technique, and patient selection, with inclusion and exclusion criteria, as well as the follow-up protocol for this trial and 12-month outcome, have been published. 4 The AI device is a unibody graft that tapers from the aortic anchoring segment to a single iliac graft limb (Fig 1) . The graft is made of woven polyester with elgiloy self-expanding, hooked anchoring stents, which are balloon dilated after deployment to enhance vessel wall attachment. The midgraft and limb are not supported. The limb is crimped to aid in patency with angulation. Trial enrollment was carried out between November 1996 and December 1998 under an Investigational Device Exemption approved by the FDA. Patients enrolled were not candidates for bifurcated endografting, because of significant iliac aneurysm disease or other iliac artery anatomic constraints.
Anatomic inclusion criteria were an ipsilateral iliac artery segment 2.5 cm or more in length that was not aneurysmal or atherosclerotic, to enable proper attachment; one ipsilateral femoral or iliac artery permitting access with a 23F (7.7 mm) device; and a contralateral femoral or iliac artery permitting access with a 16F (5.3 mm) device if common iliac artery occlusion was required. Anatomic exclusion criteria were a contralateral iliofemoral system also acceptable for bifurcated endografting or anticipated loss of adequate pelvic circulation with necessary internal iliac artery occlusion. Patients were required to be acceptable candidates for open aneurysmorrhaphy and to have at least a 2-year anticipated life expectancy, based on the medical judgment of each enrolling investigator. In addition to iliac anatomy enabling access and deployment in one iliac system, requirements included infrarenal neck length at least 15 mm and diameter no larger than 26 mm. Relative contraindications to placement, considered individually for each patient, were calcification, extensive mural thrombus, and angulation of the proximal aneurysm neck. Ipsilateral sides were chosen such that landing in the common iliac artery was preferred if feasible. If landing in the external iliac artery was required distally, the ipsilateral internal iliac artery was coil-embolized to prevent endoleak. By protocol, at least one internal iliac artery was to remain patent. Contralateral iliac system occlusion was performed with either endoluminal common iliac artery occlusion with coils or a covered stent (ENDOSOC; Guidant, Menlo Park, Calif) or a combination of external and internal iliac artery occlusion, with catheter-based internal iliac artery occlusion with surgical external iliac artery ligation from the femoral incision.
Procedures were performed in the operating room or interventional suite with appropriate operating room staff, equipment, and capability. The AI with femorofemoral crossover configuration was accomplished with surgical exposure of the femoral arteries bilaterally. After ipsilateral sheath and wire placement, appropriate aortic and iliofemoral arteriography, and systemic heparinization, a longitudinal common femoral artery arteriotomy was performed, and the AI device sheath was advanced over a super-stiff guide wire and the device deployed under fluoroscopic guidance. The proximal and distal attachments, as well as the graft limb, were balloon dilated to secure the device and fully expand the limb to eliminate any kinking or compression secondary to diseased or tortuous native iliac vessels. The sheath and guide wire were removed, and the ipsilateral anastomosis of the femorofemoral crossover bypass graft was performed, with subsequent restoration of ipsilateral leg blood flow. Proximal iliac occlusion was performed endovascularly, with subsequent completion of the femorofemoral distal anastomosis to a longitudinal contralateral common femoral arteriotomy. Completion arteriography was performed to check attachment site, AI limb, femorofemoral graft, and contralateral iliac system status.
At discharge, 6 months, and annually thereafter, all patients underwent abdominal plain film radiography, graft duplex ultrasound scanning, ankle-brachial index measurement, and fine-cut contrast-enhanced computed tomography (CT), along with physical examination. If primary endoleak was present, CT was performed at 3 months after the procedure. Independent examiners at The Cleveland Clinic core laboratory reviewed all images.
All data, including late adverse events, were recorded on trial forms as specified by the FDA and were audited for completeness and accuracy. Analyses that involved dichotomous variables were performed with the Fisher exact test. Continuous variables were evaluated with the Student t test. Actuarial analysis of mortality was performed with the Kaplan-Meier method.
RESULTS
In all, 121 patients from 15 investigational sites (Appendix) were enrolled in the AI trial; 112 patients (92.6%) were men. As reported by Moore et al, 4 intraoperative conversion was necessary in 4 (3.3%) patients. Treatment was abandoned in 3 patients (2.5%), and 1 (0.8%) patient died during surgery. Thus AI device placement was technically successful in 113 patients, who were available for long-term follow-up per protocol to evaluate graft durability. Moore et al 4 also summarized 30-day mortality (4.2%) and delineated early adverse post-repair events in this group. At repair, mean age of this cohort was 72.8 Ϯ 7.0 years. As of this writing, mean follow-up is 36.2 Ϯ 16.7 months (median, 38.0 months).
At the time of the procedure, significantly more patients in the AI cohort had congestive heart failure (17.4% vs 7.2%; P ϭ .03), cardiac arrhythmias (37.8% vs 18.9%; P ϭ .002) and peripheral arterial occlusive disease (25.6% vs 10.8%; P ϭ .004) compared with 111 control patients undergoing open aneurysmorrhaphy in the EVT/Guidant trials (Table I , online only). Mean initial aneurysm diameter in the AI cohort was 54.4 Ϯ 9.6 mm, and in 25 of 113 patients (22%) initial aneurysm diameter was less than 50 mm, as recorded by the enrolling investigators. Five specific deployment configurations were used during the trial (Fig  2) . The most common (n ϭ 54) consisted of distal CIA landing with contralateral CIA occlusion. In order of decreasing frequency the remainder were configured with distal external iliac artery landing with contralateral common iliac artery occlusion (n ϭ 32), distal common iliac artery landing with contralateral external and internal iliac artery occlusion (n ϭ 13), distal external iliac artery landing with contralateral occlusion of the external and internal iliac arteries (n ϭ 6), and any landing zone with preexisting contralateral occlusion (n ϭ 5). Distal attachment was performed in the external iliac artery in 40 patients (36%). Thus active, contralateral iliac system occlusion was necessary at endografting in 105 patients. Five patients required no active, therapeutic embolization because of preexisting chronic occlusion, and no patient underwent preoperative therapeutic contralateral iliac system occlusion. Data were not available for 3 patients. Methods of contralateral occlusion were the EVT/Guidant ENDOSOC in 62 of 105 patients, other catheter-based methods in 25 patients, and surgical ligation of the external iliac artery in 18 patients. Preexisting contralateral occlusion was present in 5 patients, and data were not available for 3 patients.
During 48 months of post-procedural follow-up, overall aneurysm diameter decreased, from 54.4 Ϯ 9.6 mm to 44.4 Ϯ 16.4 mm (Table II, online only). Among 22 patients with data at both discharge and 48 months, mean overall aneurysm diameter decreased significantly, from 54.4 Ϯ 11.9 mm to 45.5 Ϯ 16.1 mm (P ϭ .004). Aneurysm size reduction appears to stabilize 2 years after repair. Thus far, increased aneurysm diameter (Ն5 mm) is present in 3.1% of patients at 1 year after repair, 3% of patients at 2 years, 4.2% of patients at 3 years, and 9.1% of patients at 4 years (Fig 3) . Significant aneurysm expansion (Ն5 mm) developed after discharge in 4 patients, within 12 months in 3 patients and at 48 months in 1 patient. Thus 96.5% of aneurysms shrunk or remained stable. Although the incidence of significant aneurysm expansion was small, the absence of endoleak of any kind was associated with aneurysm size reduction of 5 mm or more at 24-month follow-up (P ϭ .002) and 36-month follow-up (P ϭ .008). Endoleak of any type was present in 52.3% of patients at discharge, 30.9% of patients at 1 year after repair, 34.8% of patients at 2 years, 28.6% of patients at 3 years, and 30.4% of patients at 4 years. Breakdown of endoleak by specific type is presented in Table III . Type II endoleak represents the majority. Leak from the therapeutic, active contralateral occlusion was present in 8 patients (7.2%) at discharge and in no patients after 36 months. All endoleaks sealed spontaneously without repeated intervention.
Repeated intervention because of endoleak or aneurysm enlargement was required in 17 patients (15%) over the 4-year follow-up, between 31 days and 1 year postprocedure in 6 patients, between 1 and 2 years in 5 patients, between 2 and 3 years in 4 patients, and after 3 years in 3 patients. In 1 patient with type II endoleak treated with coil embolization of the feeding lumbar arteries at 1 month post-repair, conversion to open reconstruction was necessary in month 20 because of continued leak and significant aneurysm enlargement, from 57 mm at initial endografting to 65 mm at conversion.
To date, migration of two devices has been confirmed by the core laboratory. In both cases the device moved caudad to the superior attachment site by 10 to 12 mm within the first year after placement. Neither patient has experienced endoleak or any clinical sequelae as a result of device migration. In 1 patient graft infection of the AI prosthesis developed and was treated with long-term antibiotic therapy. To date this infection has remained indolent. In 2 patients (1.8%) the aneurysm ruptured. The first patient had severe back and abdominal pain 58 months after initial repair. Follow-up examination at 48 months showed no endoleak and aneurysm regression. Six months later, the patient underwent cardiac catheterization, and the aneurysm ruptured 2 months later. Evaluation at rupture revealed ipsilateral iliac dissection and the remaining endograft in good position. It is believed the dissection disrupted the distal attachment site, leading to flow into the aneurysm sac. A covered stent was placed across the iliac artery endovascularly to seal the dissection entry, and the patient has done well since. The second rupture occurred 64 months after initial AI placement in a 93-year-old patient with abdominal pain. Follow-up imaging revealed a type II endoleak at 24 months, which resolved without intervention and has not been demonstrated since. The aneurysm had significantly decreased in size; however, the ipsilateral iliac artery had become aneurismal, leading to disruption of the distal attachment site, with retrograde aortic aneurysm filling and rupture. Endovascular stenting was used to bridge the distal attachment site disruption. The patient had acute respiratory distress syndrome postoperatively and was discharged to a skilled nursing facility, but died 3 weeks later.
Reduction in limb flow occurred in 15 (13.3%) patients. Eight patients (7.1%) required repeated interven- tion, ie, limb angioplasty and stenting, within 30 days postoperatively. Thus far, none of these patients has required further repeated intervention to assist subsequent limb patency. After 1 month, 7 patients (6.2%) required repeated intervention with limb angioplasty and stenting because of reduced limb flow. Two of these 7 patients have required further repeated intervention. In 1 patient with thigh-buttock claudication, endovascular intervention was performed in post-procedure month 24 and again in month 25. Subsequent conversion to open repair was necessary 27 months after initial placement, because of reduced limb flow. Another patient with thigh-buttock claudication underwent endovascular intervention because of limb kinking 25 months after initial repair, and then axillofemoral bypass grafting in month 28. Thus in two of 15 patients (13.3%) with reduced limb flow eventual operative correction was necessary.
Thigh or buttock claudication developed in 8 patients (7.1%) within 30 days of repair and in 8 additional patients (7.1%) more than 30 days after repair. Most of these patients (n ϭ 13; 81.3%) had either distal landing in the external iliac artery or occlusion of the contralateral internal iliac artery. Four of 16 (20%) patients have undergone intervention specifically because of thigh or buttock claudication after endografting. These interventions were angioplasty and stenting to correct reduced graft limb flow from limb kinking. Thus four of 15 patients with reduced limb flow had thigh or buttock claudication. Improvement has occurred or persistent symptoms have stabilized in all 16 patients. No progression to limb-threatening ischemia has occurred. No embolization from occluded contralateral iliac systems has been reported.
Complications directly resulting from femorofemoral bypass grafting occurred in 3 patients (2.6%), and all were graft infections. In 1 patient graft infection diagnosed 42 months after repair was treated long-term with antibiotic agents; however, at 46 months renal failure and cardiac arrhythmias developed, and the patient ultimately died. Another patient underwent graft explantation, bilateral femoral vein patching with cryopreserved human saphenous vein with bilateral sartorius muscle flaps, and contralateral axillofemoral bypass grafting 3 months after initial AI placement, but died of unrelated causes 123 days after repair. In the third patient graft infection developed 2 months after initial repair. The femorofemoral graft was explanted, and contralateral axillopopliteal bypass grafting was performed. This patient is alive. To date, no femorofemoral crossover graft has thrombosed or required revision.
Late death occurred in 41 patients (36.3%). Cause of death was cardiovascular in 14 patients (34.1%), pulmonary in 10 patients (24.4%), cancer in 10 patients (24.4%), and other cause in 7 patients (17.1%). One endograft-related death occurred after aneurysm rupture 64 months after AI placement, and one femorofemoral bypass-related death occurred 46 months after endografting. Both cases are described above. Actuarial late survival was 78.5% Ϯ 3.9% (95% confidence interval [CI], 71%-86%) at 2 years and 63.4 Ϯ 5.0% (95% CI, 54%-73%) at 4 years (Fig 4) .
DISCUSSION
Since Parodi et al 5 first described endoluminal treatment of abdominal aortic aneurysm (EVAR) in 1991, application of the technology has increased dramatically. While early reports suggested that only about 20% of patients with abdominal aortic aneurysm would be anatomically suitable for EVAR, mechanical and design enhancements have increased applicability to 50% to 60% or more of these patients. [6] [7] [8] [9] However, it has been estimated that roughly 50% of patients are excluded from EVAR because of adverse anatomic characteristics of the iliofemoral arteries. 6 If this disadvantageous iliac artery anatomy could be overcome, perhaps two thirds of patients would be potential candidates for EVAR if open repair is not considered optimal. An aortouniiliac prosthesis combined with contralateral lower extremity revascularization with femorofemoral crossover bypass grafting could overcome many of these iliac limitations if one iliac system provides adequate access and distal attachment site.
Recognized advantages to such a system include ease of device deployment, without rotational concerns, and no modular interface requirements and their potential pitfalls. Also, ease of use broadens EVAR applicability to patients with ruptured aneurysms. 10 Disadvantages unique to this repair include the potential drawbacks of femorofemoral bypass grafting, including poor late patency and infection, and development of thigh or buttock claudication when pelvic flow is disturbed by either ipsilateral or contralateral occlusion or alteration in flow. Further, occasional difficulties with therapeutic contralateral iliac system occlusion, eg, endoleak, may occur.
The feasibility and short-term success of this endovascular configuration have been reported by several authors.
1-4 Our institution's early experience with this endograft option has been reported by Rehring et al. 3 Moore et al 4 described the operative and 12-month outcomes in this EVT/Guidant AI device trial. These authors reported 30-day mortality of 4.2% in this trial and clearly delineated early morbidity. These accounts have indicated that AI endografting with femorofemoral crossover grafting can accomplish aneurysm exclusion and broaden the spectrum of patients treated endovascularly. However, continued study of the long-term issues of endograft limb patency, pelvic perfusion alterations by intentional occlusion of internal iliac arteries, consequences of contralateral iliac system occlusion, and femorofemoral bypass graft durability is critical to determine the lasting dependability of this type of repair. The purpose of this report is to continue evaluation of the recently FDA-approved EVT/Guidant AI device and the associated femorofemoral crossover graft, to better understand how its use fits into the treatment options available to the vascular surgeon.
AI endografting with femorofemoral crossover bypass grafting can produce adequate aneurysm exclusion postprocedure, as evident significant overall aneurysm diameter reduction in this cohort. Aneurysm reduction occurs within the first 24 months after repair, reaching a stable diameter afterward. After EVAR the presence of endoleak, specifically types I and III, has been reported as an independent risk factor for adverse outcome. 11, 12 While it is accepted that a majority of type II leaks will close spontaneously, their presence can retard aneurysm regression and occasionally lead to rupture. [13] [14] [15] Although the number of patients with aneurysm growth in this report is small, a relationship between endoleak and failure of the aneurysm to regress is noted after AI with femorofemoral crossover. Some may consider the rate of endoleak in this trial to be substantial. Indeed, endoleak was present in more than 50% of patients at discharge. However, after 12 months endoleak was present in 30%, which is more consistent with our institution's prior report, which delineated a 22% endoleak rate, and other available literature on bifurcated endografting. 3, 11, 16 Of interest, 17 of 58 initial patients (29%) with endoleak at discharge later require repeated intervention, and only 1 patient (1.7%) needed open conversion. It appears that endoleak can be adequately treated with catheter-based techniques in patients with this type of reconstruction configuration, with acceptable mid-term re- sults. Further, the incidence of leak from the contralateral iliac system occlusion appears small, noted in only 8 patients (7%) at discharge. Our approach has been to treat types I, III, and IV endoleaks with endoluminal methods, because of their clear correlation to poor endograft outcome, and to observe type II endoleaks unless aneurysm enlargement occurs or they persist for more than 12 months.
Graft limb problems after EVAR most commonly include kinking and thrombosis. In our institution's recently reported endografting experience, Dattilo et al 17 found limb kinking or thrombosis in some 4% of patients after primary endografting. Similarly rare results were documented in the EUROSTAR registry. 18 Fairman et al 19 reported limb interventions necessary when using the bifurcated EVT/Guidant endograft. They found that nearly 40% of patients required either intra-procedure or postprocedure intervention on graft limbs. The rate of limb interventions necessary after repair with the bifurcated device was 11.6%. These authors suggested that prophylactic stenting of the Ancure system limbs may be warranted. Postoperative limb interventions with the AI device were necessary in 15 patients (13.3%) with only one endograft limb at risk. This is not surprising, and it likely represents the more complex iliac anatomy in patients with the AI device, as well as the unsupported limb. In addition, endoluminal therapy, eg, thrombolysis or angioplasty and stenting, was successful in more than 85% of patients with the AI device with limb compromise, and only 2 patients with reduced limb flow required operative correction. Clearly, while patients with the AI device have a higher complexity of iliac disease, catheter-based interventions for reduced limb flow can be just as successful as in those with bifurcated endografts. However, the rate of reduced limb flow with the AI device in conjunction with required limb interventions adds validity to the thoughts of Fairman et al 19 regarding the unsupported limbs of the EVT/Guidant device.
The rate of migration (1.8%) and late aneurysm rupture (1.8%) in this AI trial is similar to that reported in the literature. 12, 16 While migration may limit durability of an endovascular device, the altered outflow with an AI device compared with a bifurcated device does not seem to place it at higher risk for migration. We have not aggressively treated device migration unless it has caused attachment site endoleak or led to severe device malformation. Thus far, AI rupture experience is related to iliac artery disease in this cohort. In 1 patient iliac artery dissection developed after catheterization, with subsequent aneurysm rupture, and in another patient dissection was related to late continuing iliac artery aneurysm degeneration, with loss of distal seal integrity, retrograde filling of the aneurysm, and rupture. These events were probably related to disease progression rather than to technical device failure. The AI with femorofemoral crossover configuration does not increase risk for rupture.
AI with femorofemoral crossover, by definition, alters pelvic blood flow. The potential for buttock claudication from either intentional internal iliac artery occlusion or contralateral iliac system occlusion is real. Development and relative benignity of thigh or buttock claudication after this type of reconstruction have been reported. 2, 3 Recently, Lee et al 20 described the real but small risks associated with internal iliac artery occlusion to facilitate EVAR; thigh or buttock claudication was most common. The current evaluation is clearly corroborative. Although nearly 15% of patients had thigh or buttock claudication after AI with femorofemoral crossover, most experienced attenuation or stabilization of pain, likely related to collateral vessel formation from either cross-pelvic flow or the lumbar and epigastric vessels. Occlusion of the internal iliac artery appears to be associated with thigh or buttock claudication, because 80% of patients with this complication had either distal landing in the external iliac artery or embolization of the contralateral internal iliac artery. Either internal iliac artery revascularization or newer flared iliac limbs that enable landing proximal to the iliac bifurcation are potential methods to avert these maneuvers; however, their effect on pelvic flow and claudication remains unclear.
Initial skepticism for the success of AI endografting with femorofemoral bypass was also partly due to longterm results of femorofemoral bypass in patients with lower extremity occlusive disease. 21 However, early patency results of femorofemoral bypass after EVAR have been encouraging. 4 In our earlier report of AI placement in 51 patients, 2-year primary patency of the femorofemoral graft was 97.8%. 3 In this trial, no graft thromboses occurred at a mean of 37 months. This has been attributed to the usually good distal runoff in patients with aneurysm compared with those with occlusive disease. 22, 23 Patency of the femorofemoral crossover bypass graft does not appear to compromise late outcome of this reconstruction configuration. The major complication of femorofemoral grafting in this trial was infection. According to Rutherford et al 22 and Thompson et al, 23 infection occurs in up to 4% to 5% of patients with this method of revascularization. The 2.6% infection rate in this trial is similar.
In conclusion, AI endografting in conjunction with femorofemoral crossover bypass grafting with the EVT/ Guidant device appears safe and effective. Adequate midterm aneurysm exclusion can be achieved in most patients, and most post-repair complications can be treated endovascularly. This reconstruction option offers an effective treatment alternative in patients at high risk for open repair who have unilateral iliac artery anatomy unsuitable for bifurcated endografting. The unique features of this endovascular reconstruction, in particular femorofemoral grafting and contralateral iliac system occlusion, do not appear overly problematic.
